ISB 2001 demonstrated a favorable safety and tolerability profile, and an overall response rate (ORR) of 75% in r/r MM
Raises 2024 revenue guidance to a range of US$ 61 to US$ 64 billion
Partnership to Combine AbbVie's Oncology Expertise with EvolveImmune's Proprietary EVOLVE T-Cell Engager Platform to Develop Novel Multispecific Therapeutic Antibodies for Cancer
Lupin's R&D teams are working on products with a near-zero global warming potential propellant
Strengthening focus in Alzheimer's disease and neuroscience pipeline
CMG1A46 is an investigational T cell-engager with potential to deeply deplete uncontrolled B cells present in autoimmune diseases such as lupus
Potential to optimize and build on the synergies in commercial operations, distribution, manufacturing, supply chain etc.
This partnership will enable healthcare organizations to provide best-in-class patient/consumer experiences
Giri is currently the President (India Business & Emerging Markets) of Amneal Pharmaceuticals
VYALEV is the first and only subcutaneous 24-hour continuous infusion of levodopa-based therapy for the treatment of motor fluctuations in advanced Parkinson's disease
Subscribe To Our Newsletter & Stay Updated
